A 24 week randomised, open label, 3 parallel-group comparison of once and twice daily biphasic insulin aspart (BIAsp) 30 plus sitagliptin and twice daily BIAsp 30, all in combination with metformin in insulin naive type 2 diabetic subjects inadequately controlled on sitagliptin and metformin - SIT2MIX
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SIT2MIX
- Sponsors Novo Nordisk
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Oct 2012 New source identified and integrated (Clinical Trials Registry - India, CTRI2012-10-003041).